Cancer epidemiology in Central and South Eastern European countries by Vrdoljak, Eduard et al.
478
www.cmj.hr
Aim To collect cancer epidemiology data in South Eastern 
European countries as a basis for potential comparison of 
their performance in cancer care.
Methods The South Eastern European Research Oncology 
Group (SEEROG) collected and analyzed epidemiological 
data on incidence and mortality that reflect cancer man-
agement in 8 countries – Croatia, Czech Republic, Hunga-
ry, Romania, Poland, Slovakia, and Serbia and Montenegro 
in the last 20-40 years.
Results The most common cancer type in men in all coun-
tries was lung cancer, followed by colorectal and prostate 
cancer, with the exception of the Czech Republic, where 
prostate cancer and colorectal cancer were more com-
mon. The most frequent cancer in women was breast can-
cer followed by colorectal cancer, with the exceptions of 
Romania and Central Serbia where cervical cancer was the 
second most common. Cancer mortality data from the last 
20-40 years revealed two different patterns in men. In Ro-
mania and in Serbia and Montenegro, there was a trend 
toward an increase, while in the other countries mortali-
ty was declining, after increasing for a number of years. In 
women, a steady decline was observed over many years 
in the Czech Republic, Hungary, and Slovakia, while in the 
other countries it remained unchanged.
Conclusions There are striking variations in the risk of dif-
ferent cancers by geographic area. Most of the interna-
tional variation is due to exposure to known or suspected 
risk factors which provides a clear challenge to prevention. 
There are some differences in incidence and mortality that 
cannot be explained by exposure to known risk factors or 
treatment availabilities.
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On  a  global  scale,  cancer  has  become  a  major  public 
health problem and an increasingly important contributor 
to the burden of disease. Based on the most recent avail-
able international data, there were an estimated 12.7 mil-
lion new cancer cases, 7.6 million deaths from cancer, and 
28 million persons alive with cancer within five years from 
the initial diagnosis (1-3). The most common cancers in the 
world were lung (1.61 million cases), breast (1.38 million), 
and colorectal cancer (1.24 million) (3). Because of its poor 
prognosis, lung cancer was also the most common cause 
of death (1.38 million), followed by gastric (737 000 deaths), 
and liver cancer (695 000 deaths) (1-4).
Priority setting for cancer control and cancer services in 
any region needs to be based on knowledge of the can-
cer burden and the local mix of predominant cancer types 
(5). According to estimates of global cancer burden made 
by the International Agency for Research on Cancer (IARC), 
the incidence and mortality rates from many specific types 
of cancer and all cancers combined vary widely by geo-
graphic locality (6). Moreover, the IARC also estimated that 
over half of newly diagnosed cases and two-thirds of can-
cer deaths occur in low and medium-income countries (6). 
There are striking variations in the pattern of cancer by site 
from region to region (7). The large differences in incidence 
and mortality in different countries may reflect a combina-
tion of differences in prevalence of underlying risk factors, 
differences in host susceptibility, and/or variations in can-
cer detection, reporting, classification systems, treatment, 
and  follow-up.  Among  European  countries,  wide  differ-
ences in the quality of cancer care are observed, especial-
ly when comparison is made between “old” and “new” EU 
members or between developed and developing coun-
tries (8). Cancer survival is significantly lower in Eastern Eu-
ropean countries, including the new Member States, than 
in the EU 15 (9-12). Transitional countries and middle in-
come countries are frequently left forgotten “in between” 
and the cancer problem in these countries is among the 
worst and fastest growing (8).
In this report, we provide an analysis, which we propose as 
a foundation for detailed evaluation of cancer care in se-
lected Central, Southern and Eastern European countries, 
represented by members of the South Eastern European 
Research Oncology Group (SEEROG). Our epidemiological 
analysis indicates the scale of the problem of oncological 
care in individual countries and shows current trends in 
the incidence of particular cancers. Comparison of status 
of oncology between countries in Eastern, Southern, and 
Central European region has never been undertaken be-
fore and key barriers to deliver appropriate quality of care 
have not previously been identified.
MATERiAl ANd METhOdS
The methods used to compute the estimates for major 
cancers are described in detail in GLOBOCAN (1). The basic 
data used are the best available information on incidence 
and mortality in selected SEEROG countries. We estimat-
ed the incidence and mortality rates for selected South-
ern and Eastern European countries by sex and cancer site, 
for four age groups (0-19, 20-44, 45-64, 65+ years) using 
the most recent data. The countries included in the analy-
sis were Croatia, Czech Republic, Hungary, Poland, Roma-
nia, Slovakia, and Serbia and Montenegro. Estimates of the 
resident population of individual countries for the years 
2002 to 2006, generally based on official censuses, were 
obtained from the World Health Organization (WHO) da-
tabase.  Age-standardized  incidence  and  mortality  rates 
per 100 000 populations were calculated. From the matri-
ces of certified deaths and resident population numbers, 
incidence and mortality rates were calculated for specific 
age groups (0-19, 20-44, 45-64, 65+ years) and time peri-
ods. The world standard population was used for calcula-
tions (13).
Historical data on cancer mortality rates covered the pe-
riod from the early 1960s to the first decade of the 21st 
century. The time frame for the individual countries was: 
Croatia  1985-2006;  Czech  Republic  1970-2005;  Hungary 
1965-2005; Poland 1965-2006; Romania 1969-2004; Serbia 
and Montenegro 1997-2002 (although Serbia and Mon-
tenegro  are  now  two  independent  countries,  we  pres-
ent results for both countries together as over this period 
they were one state); and Slovakia 1971-2005. The data 
for specific tumor sites were abstracted from WHO data-
base, including the number of deaths by sex and 5-year 
age groups according to cancer site in the relevant years 
(14). Mortality data were collected for all cancers and for 
selected cancer sites by searching for the following In-
ternational Classification of Diseases version 10 (ICD-10) 
codes: cancer general (C00-C97), stomach (C16), colorec-
tal (C18-C21), lung (C33-C34), breast (C50), uterine cervix 
(C53), ovary (C56), prostate (C61), kidney (C64), and urinary 
bladder (C67). For long-term observations, the source data 
were re-coded into ICD-10 according to the recommen-
dations of the ICD and WHO committee (15).
Sources of data on incidence are much more disparate. 
Attempts were made to collect data for the whole FORUM 480 Croat Med J. 2011; 52: 478-87
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of each country. The sources of data and time frames were 
as follows:
1. Croatia: Croatian National Cancer Registry, Croatian Na-
tional Institute of Public Health, Zagreb; 1993-2006 (16);
2. The  Czech  Republic:  Czech  National  Cancer  Registry; 
1977-2005 (17);
3. Hungary: Globocan 2002 (process of creating national 
cancer register has been started but it ended with project 
phase) (1);
4. Poland: National Cancer Register; 1980-2006 (18);
5. Romania: Globocan 2002 (there are some local registers; 
however, these registers significantly underestimated inci-
dence; until 2007, registration was at the hospital and clin-
TABlE 1. Population characteristics of the selected countries: 
Croatia, Czech Republic, hungary, Poland, Romania, Serbia and 
Montenegro, and Slovakia
Year of data
Population 
(in thousands)
Country collection male female total
Croatia 2005   2138.6   2303.3   4441.9
Czech Republic 2005   4991.4   5242.7 10 234.1
Hungary 2005   4788.8   5298.2 10 087.1
Poland 2006 18 436.1 19 696.2 38 132.3
Romania 2004 10 571.6 11 101.7 21 673.3
Serbia and Montenegro 2002   3947.1   4161.5   8108.7
Slovakia 2005   2615.9   2773.3   5389.2
TABlE 2. Age-standardized incidence rates for all cancers by sex and country – Croatia, Czech Republic, hungary, Poland, Romania, 
Central Serbia, and Slovakia (last available year)
Year of data Male Female
Country collection n 0-19 20-44 45-64 65+ all ages n 0-19 20-44 45-64 65+ all ages
Croatia 2005 11 030 19.1 71.1 655.4 2255.2 314.2   9156 16.3   94.2 506.4 1078.8 210.3
Czech Republic 2005 28 147 12.7 64.4 761.5 2676.7 359.0 26 627 12.0 170.4 647.0 1439.1 286.4
Hungary 2002 26 278 11.5 78.7 916.1 2504.9 386.8 22 924   9.1   93.8 582.9 1381.7 250.6
Poland 2006 64 092 13.8 46.0 553.3 1818.5 253.6 61 927 12.1   76.6 506.5   923.1 191.8
Romania 2002 32 244 12.3 53.9 544.9 1226.1 216.4 27 655   9.9   84.0 397.3 696.2 163.4
Central Serbia 2004 12 801 21.7 84.3 692.8 1674.7 286.2 11 954 17.1 134.4 640.4 1036.5 246.7
Slovakia 2003 12 159 16.9 73.2 807.4 2662.5 371.4 11 841 12.5   95.9 627.5 1443.4 257.9
TABlE 3. Age-standardized incidence rates for selected cancers (available year) by country Croatia, Czech Republic, hungary, Poland, 
Romania, Serbia and Montenegro, and Slovakia
Male Female
Country
Year of data
collection lung stomach
large
bowel prostatekidney
urinary 
bladder lungstomach
large
bowel breast cervix ovarykidney
urinary 
bladder
Croatia 2005 63.7 17.7 43.5 38.7 11.1 18.4 13.6 6.9 23.4 55.8   9.2 11.7 4.7 4.1
Czech 
Republic
2005 58.2 11.2 58.7 59.5 22.6 22.3 15.5 5.8 28.8 61.7 13.3 12.4 9.8 6.0
Hungary 2002 94.6 20.5 56.6 34.0 14.7 19.6 24.9 9.5 33.7 63.0 15.7 11.1 6.6 5.1
Poland 2006 60.2 12.8 29.3 27.3   9.1 15.9 14.5 4.9 17.2 44.5 11.5 11.1 4.7 3.0
Romania 2002 50.0 17.6 22.0 16.8   5.5 15.4   8.5 6.8 14.4 44.3 23.9   9.4 2.8 3.3
Central Serbia 2004 64.2 12.9 33.7 20.1   6.5 17.4 18.4 7.2 20.9 57.9 24.3 10.9 3.8 4.2
Slovakia 2004 55.8 16.1 55.5 33.9 14.9 15.9 10.4 7.0 27.7 49.7 15.2 11.5 6.6 4.1
TABlE 4. Cancer mortality compared to total mortality by country – Croatia, Czech Republic, hungary, Poland, Romania, Serbia and 
Montenegro, and Slovakia
Year of data
Population 
(in thousands)
Number of 
total deaths
All 
cancer deaths
Frequency of 
cancer deaths (%)
Country collection male female total male female total male female total male female total
Croatia 2005   2138.6   2303.3   4441.9   26 058   25 720   51 778    7430    5209 12 639 29 20 24
Czech Republic 2005   4991.4   5242.7 10 234.1   54 072   53 866 107 938 15 567 12 466 28 033 29 23 26
Hungary 2005   4788.8   5298.2 10 087.1   69 773   65 950 135 723 17 134 13 481 30 615 25 20 23
Poland 2006 18 436.1 19 696.2 38 132.3 198 298 171 388 369 686 51 777 39 855 91 632 26 23 25
Romania 2004 10 571.6 11 101.7 21 673.3 138 440 120 450 258 890 25 641 18 037 43 678 19 15 17
Serbia and Montenegro 2002   3947.1   4161.5   8108.7 111 108 105 350   216 458 11 216    8330 19 546 10  8  9
Slovakia 2005   2615.9   2773.3  5  389.2   28 151   25 324   53 475    6906    4888 11 794 25 19 22481 Vrdoljak et al: Cancer epidemiology in European transitional countries
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ic level and there were no national institution collecting 
data) (1).
6. Serbia: Cancer Registry of Central Serbia, Institute of Pub-
lic Health of the Republic of Serbia (75% of Serbian popula-
tion) 2002-2004 (19).
7. Montenegro: there is no reliable source of data on can-
cer incidence in Montenegro as a whole, but the data were 
derived from cancer registries covering a part of the coun-
try (19).
8. Slovakia: National Cancer Registry, Cancer Research Insti-
tute SAS, Bratislava; 1978-2003 (20).
RESulTS
The analysis covered a total population of 98 million peo-
ple in all the participating countries. The population sizes 
of the chosen countries ranged from 4.5 million in Croatia 
to 38 million in Poland (Table 1).
incidence
There were almost 360 000 newly diagnosed cancer pa-
tients per year in the study region. The greatest number 
based  on  the  size  of  populations  was  found  in  Poland 
(n=126 019) and Croatia (n=20 186) (Table 2).
Detailed  analysis  by  age  showed  that  in  children  (0-19 
years) the highest cancer incidence was observed in Cen-
tral  Serbia  (21.7/100 000  for  boys  and  17.1/100 000  for 
girls) and Croatia (19.1/100 000 and 16.3/100 000, respec-
tively). The lowest incidences were recorded in Hungary 
(11.5/100 000 and 9.1/100 000, respectively) and Romania 
(12.3/100 000  and  9.9/100 000,  respectively).  In  this  age 
group, cancer was diagnosed more frequently in boys than 
in girls, by approximately 20% (Table 2).
Cancer incidence in young adults (20-44 years) was signifi-
cantly higher in women than in men in most countries. In-
cidence rates in women were between 76.6/100 000 in Po-
land and 170.4/100 000 in Czech Republic, which is a much 
greater difference than between the rates in men in that age 
group. The incidence in men was highest in Central Serbia 
(84.3/100 000) and lowest in Poland (46.0/100 000) (Table 2).
In  the  middle-aged  population  (45-64  years),  cancer  in-
cidence  was  about  30%  higher  in  men  than  in  wom-
en. The highest incidence in men was found in Hungary 
(916.1/100 000)  and  the  lowest  in  Poland  (553.3/100 000) 
and Romania (544.9/100 000). The highest cancer incidence 
in women in this age group was in the Czech Republic, Cen-
tral Serbia, and Slovakia (≥627.5/100 000). The lowest inci-
dence was estimated for Romania (397.3/100 000) (Table 2).
TABlE 5. Standardized mortality rates from all cancers in selected countries – Croatia, Czech Republic, hungary, Poland, Romania, 
Serbia and Montenegro, and Slovakia by age group and sex
Male Female
Country 0-19 20-44 45-64 65+ all ages 0-19 20-44 45-64 65+ all ages
Croatia 3.9 22.5 410.6 1674.7 204.4 3.8 19.6 197.6 746.4   98.0
Czech Republic 2.6 17.7 375.1 1643.5 193.4 2.2 19.3 223.3 856.4 109.8
Hungary 3.4 30.8 563.8 1530.3 226.1 2.7 28.9 275.0 785.7 118.1
Poland 4.3 19.3 396.1 1602.9 195.7 3.5 20.2 243.8 725.9 105.4
Romania 6.5 28.1 404.6 1082.7 164.8 4.8 30.9 210.7 560.1   91.6
Serbia and Montenegro 5.6 25.9 388.3 1148.3 165.2 4.0 29.2 249.9 624.0 102.7
Slovakia 4.1 20.7 428.1 1594.1 201.6 4.0 18.9 218.3 707.9   99.1
TABlE 6. Age-standardized selected cancers mortality rates in selected countries (Croatia, Czech Republic, hungary, Poland, Roma-
nia, Slovakia in 2005, and Serbia and Montenegro in 2002)
Male Female
Country lung stomach
large
bowel prostate kidney
urinary
bladder lung stomach
large
bowel breast cervix ovary kidney
urinary
bladder
Croatia 55.3 14.3 25.0 15.3 4.9 6.3 10.7 5.9 12.0 17.4   2.5 5.7 1.8 1.2
Czech Republic 52.4   9.3 30.0 16.3 9.2 5.9 12.8 4.6 14.2 17.7   3.9 7.4 3.5 1.5
Hungary 72.5 12.4 31.9 13.0 5.4 6.9 22.3 5.8 16.4 19.2   4.9 5.6 2.2 1.6
Poland 64.6 13.6 18.8 12.9 5.8 8.0 14.3 4.9 10.8 14.9   5.7 7.0 2.2 1.3
Romania 48.2 15.4 15.6   9.0 2.8 5.7   8.5 5.3   9.1 16.6 10.7 5.4 1.1 1.1
Serbia and Montenegro 51.9 11.5 18.4   9.5 2.9 6.2 12.3 4.7 10.1 19.3   6.9 4.4 1.6 1.1
Slovakia 50.5 12.0 30.6 14.9 5.9 5.4   7.8 5.7 13.3 15.3   5.1 5.9 2.7 1.2FORUM 482 Croat Med J. 2011; 52: 478-87
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In  the  elderly  population  (≥65  years),  cancer  was  diag-
nosed almost twice as often in men as in women. The 
highest incidence in older men was found in the Czech 
Republic  (2676.7/100 000)  and  Slovakia  (2662.5/100 000) 
and the lowest in Romania (1226.1/100 000). The pattern of 
cancer incidence in older women was the same as in old-
er men: the highest in Slovakia (1443.4/100 000) and the 
Czech Republic (1439.1/100 000), and the lowest in Poland 
(923.1/100 000) and Romania (696.2/100 000) (Table 2).
Table 3 shows age-standardized incidence rates for the se-
lected most common cancer sites.
Lung cancer was the most common cancer in men in 
all studied countries, with the exception of the Czech 
Republic,  where  prostate  cancer  and  colorectal  cancer 
were more common. The second most frequent cause of 
cancer morbidity was colorectal cancer followed by pros-
tate cancer, which was ranked third in most countries, with 
the highest proportion in the Czech Republic and the low-
est proportion in Central Serbia. The incidence of kidney 
cancer ranged from ~ 2% in most countries to 6.3% in the 
Czech Republic. The latter is a special case, with a kidney 
cancer incidence 2-4 times higher than other countries in 
the region. The most frequent cancer in women was breast 
cancer, with the highest incidence in Romania and the low-
est in Slovakia. The second most common tumor was col-
orectal cancer. An exception was Romania, where cervical 
cancer was the second most common cancer in women. 
In the third place, there was lung cancer (Croatia, Hungary, 
Figure 1.
 Overview of cancer incidence by site and sex for selected countries – Croatia, hungary, Romania, Central Serbia, Poland, and Slovakia.483 Vrdoljak et al: Cancer epidemiology in European transitional countries
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Poland, and Central Serbia), uterine cancer (Czech Repub-
lic, Slovakia), or colorectal cancer (Romania). Kidney cancer 
was responsible for 2-4% of the cancer incidence (highest 
in the Czech Republic). Figure 1 gives an overview of can-
cer incidence by site, sex, and country.
Mortality
The greatest number of cancer deaths was observed in 
Poland (91 632), which had the biggest population of the 
studied countries and the fewest cancer deaths occurred 
in Slovakia (n=11 794) and Croatia (n=12 639), attributed to 
the smaller size of the populations (Table 4).
The proportion of deaths attributable to cancer was high-
est for men in Croatia and the Czech Republic (29%), while 
in Poland and Hungary about a quarter of deaths were 
caused by cancer. The highest proportion of cancer deaths 
in women was found in Poland and the Czech Republic 
(23%), while in other countries (except Romania, and Ser-
bia and Montenegro) cancer deaths constituted a fifth of 
all deaths (Table 4).
Table 5 presents cancer mortality data by age group. In 
the  0-19  years  age  group,  the  highest  cancer  mortal-
ity in boys was found in Romania (6.5/100 000) and Ser-
bia and Montenegro (5.6/100 000) and in girls in Roma-
nia (4.8/100 000). The lowest cancer mortality in this age 
group was recorded in the Czech Republic and Hungary 
(2.2-3.4/100 000). In the 20-44 years age group, the high-
est cancer mortality in men was observed in Hungary 
(30.8/100 000) and Romania (28.1/100 000). Women had 
the highest cancer mortality in Romania (30.9/100 000), 
Serbia  and  Montenegro  (29.2/100000),  and  Hungary 
(28.9/100000). In the other countries, the cancer mortality 
rates were similar and about 50% lower. In this age group, 
cancer mortality rates in women were equal to or higher 
than rates in men. Significantly higher cancer mortality 
rates in men aged 45-64 years were observed in Hunga-
ry, with the rate of 563.8/100 000 being 30%-50% higher 
than in other countries. Similarly in the female popula-
tion, mortality was highest in Hungary (275.0/100 000) 
and  lowest  in  Romania  (210.7/100 000)  and  Croatia 
(197.6/100 000).  Cancer  mortality  in  elderly  men  (≥65 
years) was similar in Croatia, the Czech Republic, Poland, 
and Slovakia (1550-1675/100 000). Cancer mortality was 
about 30%-35% lower ( ~ 1100/100 000) in Romania and 
Serbia and Montenegro. In women, a similar pattern was 
observed, with the lowest mortality in Serbia and Monte-
negro and Romania.
In  women,  the  highest  cancer  mortality  was  found 
in  Hungary  (118.1/100 000)  and  the  Czech  Republic 
(109.8/100 000) and the lowest in Romania (91.6/100 000) 
and Croatia (98/100 000) (Table 5).
Table 6 presents cancer mortality data by selected, the most 
common cancer sites. In most countries, the highest pro-
portion of cancer mortality in men was attributed to lung 
cancer, followed by colorectal cancer and prostate cancer. 
In Romania, the ranking was different, with stomach can-
cer in the second place. Similarly, in Serbia and Montene-
gro, stomach cancer was the third cause of cancer mortal-
ity, followed by prostate cancer. The next positions among 
the ten most frequent cancers are occupied by pancreatic 
cancer, bladder cancer, liver cancer, laryngeal cancer, leu-
kemia, esophageal cancer, and kidney cancer. Esophageal 
cancer was in the first ten in the Czech Republic, Slovakia, 
and Hungary, while kidney cancer was in the first ten in 
Croatia, Czech Republic, Poland, and Slovakia. In women, 
breast cancer had a dominant position in most countries. 
The proportion of cancer deaths due to breast cancer was 
between 13.1% (Poland) and 17.7% (Croatia). However, in 
two countries other cancer types caused more deaths in 
women: lung cancer and colorectal cancer in Hungary and 
colorectal cancer in Slovakia. Colorectal cancer and lung 
cancer were in second place, causing a similar proportion 
in cancer mortality. The next positions were taken by pan-
creatic cancer, ovarian cancer, and stomach cancer. In Ro-
mania, cervical cancer was the third most common cause 
of cancer deaths. This phenomenon was not observed in 
other countries.
The distribution of cancer deaths in men and women by 
site of tumor is presented in Figure 2.
Mortality trends from all cancers in the last 20-40 years (de-
pending on data available) are shown in Figure 3.
Cancer mortality trends in the last 20-40 years show that 
there are two conflicting patterns in men. In Romania and 
Serbia and Montenegro, an increasing trend was observed 
while in other countries, after many years of increasing 
cancer mortality, rates were decreasing. The most signif-
icant decrease in cancer mortality was recorded in the 
Czech Republic and Slovakia. In the female population, 
an improving trend was observed in the Czech Repub-
lic, Hungary, and Slovakia, with a constant decrease in 
cancer mortality over many years in these countries. In 
other countries, cancer mortality in women remained 
unchanged.FORUM 484 Croat Med J. 2011; 52: 478-87
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diSCuSSiON
There are striking variations in cancer epidemiology and 
in quality of cancer care in different regions of the world 
(7).  Differences  in  quality  of  cancer  care  have  been 
observed  between  European  countries,  especial-
ly when “old” and “new” EU member states are compared 
(11,21,22). This study provides updated estimates of cancer 
epidemiology in eight selected Central, South and East Eu-
ropean countries. Several sources of information and differ-
ent methods have been used to generate these statistics. 
In general, the cancer problem is worst and fastest grow-
Figure 2.
Cancer deaths for 10 cancer sites by sex for selected countries – Croatia, Czech Republic, hungary, Romania, Central Serbia, Poland, and Slovakia.485 Vrdoljak et al: Cancer epidemiology in European transitional countries
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ing among developing countries and hence prompt ac-
tion is needed using all known anticancer strategies, from 
primary prevention to early detection and adoption of the 
best available anticancer treatments (21). As mentioned, 
this article describes the cancer epidemiology situations in 
selected Central, South and Eastern European countries in 
order to address the specific problems and needs of differ-
ent countries.
The highest cancer incidence in men was found in Hun-
gary (386.8/100,000), while the rates in Poland, Central Ser-
bia, and Croatia were lower by a third and in Romania by 
half (Table 2). In women, the highest incidence rates were 
found in the Czech Republic (286.4/100 000) and Slovakia 
(257.9/100 000). The lowest incidence, below 200/100 000, 
was noted in Poland and Romania. Unfortunately, the ob-
served age-standardized incidence rates are among the 
highest in the world, underlining the urgent need to invest 
more in the fight against cancer (1,3).
Detailed analysis by age showing differences in the in-
cidence of cancer in the age group 0-19 years of almost 
50% in such a small region and between relatively simi-
larly developed countries implies possible differences in 
the prevalence of underlying risk factors and differences in 
host susceptibility. However variations in cancer detection, 
reporting, classification, treatment, and follow-up may be 
even more important. For example, Romania has one of 
lowest incidence rates but the highest mortality rates, im-
plying either inadequate reporting of cancer cases (lack of 
cancer register in Romania) or challenges in cancer treat-
ment in patients in this age group.
The  observation  that  cancer  incidence  in  young  adults 
(20-44 years) is significantly higher in women than in men 
in most countries is in line with similar observation from 
Western Europe (1). But, in some countries such as the 
Czech Republic differences are three times higher, which 
warrants further investigations. Nevertheless, despite huge 
differences in incidence between the sexes, the mortality 
rates are similar, indicating the fact that women have more 
treatable tumors and better survival rates. In the middle-
aged population (45-64 years), cancer incidence was about 
30% higher in men than in women. Such difference in inci-
dence rates results in even greater difference in mortality, 
meaning that men have double chance of dying of cancer 
than women. In the elderly population (≥65 years), cancer 
was diagnosed almost twice as often in men as in women. 
Cancer mortality in elderly men (≥65 years) was similar in 
Croatia, the Czech Republic, Poland, and Slovakia (1550-
1675/100 000). It was about 20% lower ( ~ 1100/100 000) in 
Romania and Serbia and Montenegro. In women, a similar 
pattern was observed, with the lowest mortality in Serbia 
and Montenegro and Romania.
In the former 15 EU countries, mortality trends for all cancer 
sites were more favorable than in Central and Eastern Euro-
pean accession countries that entered the EU in 2004 and 
2007, including Hungary, Czech Republic, Poland, Slovakia, 
and Romania (10,11). In particular, these countries had the 
highest rates not only for lung cancer and other tobac-
co-related cancers, but also for gastric and cervical can-
cers and leukemias (10-12). Moreover, for all cancer sites, 
trends were more favorable in the former 15 EU coun-
tries than in these countries. According to Boyle et 
Figure 3.
Mortality from all cancers over time in selected countries by sex; black 
triangle – hungary, black square – Czech Republic, black circle – Poland, 
black cross – Slovakia, black rhomb – Croatia, white circle – Serbia and 
Montenegro, gray cross – Romania.FORUM 486 Croat Med J. 2011; 52: 478-87
www.cmj.hr
al, maintenance and potential improvement of favorable 
trends in cancer mortality would require a strategy focus-
ing on the control of tobacco and alcohol consumption, 
nutrition and diet, and avoiding excessive sun exposure 
(23). Unfortunately, the highest tobacco consumption in 
Europe is in its Eastern part and highest alcohol consump-
tion in the central part, particularly in the Czech Republic in 
which the average daily consumption was 56.9 g/L in men 
and 14.6g/L in women (24). For selected cancer sites, early 
diagnosis can also have a relevant impact, and this together 
with the universal adoption of recent therapeutic advanc-
es in countries from Central, South, and Eastern Europe 
may contribute to reducing the cancer mortality burden, 
as was most probably the case with cervical cancer mortal-
ity in Romania and Central Serbia (10,11). In 2000, total can-
cer mortality for men in the EU was 165.6/100 000, whereas 
total cancer mortality rates in the eight Central and Eastern 
European accession countries ranged from 194.5/100 000 
in  Lithuania  to  269.3/100 000  in  Hungary  (10). The  me-
dian cancer mortality rate in men for all countries in this 
SEEROG analysis was 193.02/100 000 (from 164.8/100 000 
in Romania to 226.1/100 000 in Hungary). This cancer mor-
tality rate was significantly higher than in five Western Eu-
ropean countries (median 146.9/100 000 in 2005); the rates 
by country are: 152.4/100 000 in Spain, 163.6/100 000 in 
France, 138.7/100 000 in the UK, 136.4/100 000 in Ireland, 
and  143.2/100 000  in  Germany  (10). The  cancer  mortal-
ity rates for women in the SEEROG countries ranged from 
91.6/100 000 in Romania to 118.1/100 000 in Hungary, while 
in the five Western European countries the rates ranged 
from 69.4/100 000 in Spain to 105.8/100 000 in Ireland. The 
median cancer mortality rate in the SEEROG countries was 
103.52/100 000, compared with 89.72/100 000 in five West-
ern European countries.
The most important factors that influence cancer mortality 
rates are adequate cancer screening, diagnosis, and treat-
ment (10,25). Also, and no less important, is the distribution 
of different types of cancer. Namely, while prostatic cancer 
is becoming the most common type of cancer in devel-
oped countries, lung cancer, a significantly more deadly tu-
mor type, is the most prevalent cancer in the developing 
world. The excess mortality from these neoplasms in East-
ern European countries could therefore be reduced if ade-
quate resources, training, and logistics to deliver adequate 
diagnosis and treatment were implemented (26-29).
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